(S)-[6]-Gingerol inhibits TGF-β-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 7, 2013, Pages 1026-1036

  Kamato, Danielle ^a   Babaahmadi Rezaei, Hossein ^a,d   Getachew, Robel ^a   Thach, Lyna ^a   Guidone, Daniel ^a   Osman, Narin ^a,b   Roufogalis, Basil ^c   Duke, Colin C ^c   Tran, Van Hoan ^c   Zheng, Wenhua ^e   Little, Peter J ^a,b  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SUN YAT SEN UNIVERSITY   (China)

Author keywords

(S) 6 Gingerol; biglycan; proteoglycans; Smad signalling

Indexed keywords

(6) GINGEROL; BIGLYCAN; GLYCOSAMINOGLYCAN; MESSENGER RNA; PROTEIN KINASE B; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEOGLYCAN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ATHEROSCLEROSIS; BIGLYCAN; BLOTTING, WESTERN; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; GLYCOSAMINOGLYCANS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84878794949     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12060     Document Type: Article

References (46)

1. Bhattarai S, et al. The stability of gingerol and shogaol in aqueous solutions. J Pharm Sci 2001; 90: 1658-1664.
2. Lee HS, et al. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J Nutr Biochem 2008; 19: 313-319.
3. Nammi S, et al. Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. Basic Clin Pharmacol Toxicol 2009; 104: 366-373.
4. Nammi S, et al. Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase expression by Zingiber officinale in the liver of high-fat diet-fed rats. Basic Clin Pharmacol Toxicol 2010; 106: 389-395.
5. Kim EC, et al. [6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2005; 335: 300-308.
6. Nurtjahja-Tjendraputra E, et al. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res 2003; 111: 259-265.
7. Hozawa A, et al. Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects-Atherosclerosis Risk in Communities Study. Arch Intern Med 2007; 167: 573-579.
8. Libby P,. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-460S.
9. Falk E,. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63: 114E-120E.
10. Richardson PD, et al. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-944.
11. Tabas I, et al. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116: 1832-1844.
12. Camejo G,. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv Lipid Res 1982; 19: 1-53.
13. Ballinger ML, et al. Regulation of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci 2004; 61: 1296-1306.
14. Little PJ, et al. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 2008; 19: 448-454.
15. Ballinger ML, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med 2010; 14: 1408-1418.
16. Gustafsson M, et al. Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase. Circ Res 2007; 101: 777-783.
17. Anggraeni VY, et al. Correlation of C4ST-1 and ChGn-2 expression with chondroitin sulfate chain elongation in atherosclerosis. Biochem Biophys Res Commun 2011; 406: 36-41.
18. Getachew R, et al. PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. Endocrinology 2010; 151: 4356-4367.
19. Grainger DJ,. TGF-beta and atherosclerosis in man. Cardiovasc Res 2007; 74: 213-222.
20. Bobik A, et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 1999; 99: 2883-2891.
21. Little PJ, et al. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 2002; 22: 55-60.
22. Osman N, et al. TGF-beta stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle. Growth Factors 2011; 29: 203-210.
23. Dadlani H, et al. Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. J Biol Chem 2008; 283: 7844-7852.
24. Burch ML, et al. TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cell Mol Life Sci 2010; 67: 2077-2090.
25. Derynck R, Zhang YE,. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
26. Massague J,. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
27. Getachew R, et al. Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells. Eur J Pharmacol 2010; 626: 186-192.
28. Neylon CB, et al. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride- sensitive Na(+)- and HCO3(-)-dependent mechanism. Circ Res 1990; 67: 814-825.
29. Nigro J, et al. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 2002; 162: 119-129.
30. Nigro J, et al. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces LDL binding. Diabetologia 2004; 47: 2105-2113.
31. Calabro A, et al. Microanalysis of enzyme digests of hyaluronan and chondroitin/dermatan sulfate by fluorophore-assisted carbohydrate electrophoresis (FACE). Glycobiology 2000; 10: 273-281.
32. de Dios ST, et al. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J Diabetes Complications 2007; 21: 108-117.
33. Wight TN,. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-20.
34. Burch ML, et al. Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell Mol Life Sci 2011; 68: 97-107.
35. Burgering BM, Coffer PJ,. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376: 599-602.
36. Little PJ, et al. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vascular Health Risk Management 2007; 3: 1-8.
37. Nigro J, et al. Insulin resistance and atherosclerosis. Endocr Rev 2006; 27: 242-259.
38. Skalen K, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-754.
39. Kunjathoor VV, et al. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 462-468.
40. Finn AV, et al. Pharmacotherapy of coronary atherosclerosis. Expert Opin Pharmacother 2009; 10: 1587-1603.
41. kip1. J Pharmacol Sci 2008; 107: 90-98.
42. Little PJ, et al. Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFbeta receptor phosphorylation. Arch Biochem Biophys 2012; 525: 25-31.
43. Cardoso LE, et al. Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways. J Biol Chem 2010; 285: 6987-6995.
44. Koehn FE, Carter GT,. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-220.
45. Nissen SE, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-1316.
46. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.